Company: PSTV
Filing Date: 2025-03-14
Form Type: PRE 14A
Source: 0001140361-25-008857
Chunk: 23

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-03-14
Form: PRE 14A
Chunk 23
---
arrant Shares pursuant to Section 3.2 of the Series B Warrants; |

| • | to consent to any adjustment to the exercise price or number of (i) Series A Warrant Shares in the event of a Share Combination Event pursuant to Section 3.9 of the Series A Warrants, and (ii) Series B Warrant Shares in the event of a Share Combination Event pursuant to Section 3.8 of the Series B Warrants; |

| • | to consent to any voluntary adjustment, from time to time, of the exercise price of any and all currently outstanding (i) Series A Warrants pursuant to Section 3.10 of the Series A Warrants, and (ii) Series B Warrants pursuant to Section 3.9 of the Series B Warrants; and |

| • | to consent to an increase in the number of authorized shares of Common Stock under the Company’s Certificate of Incorporation from 100,000,000 shares of Common Stock to at least 2,000,000,000 shares of Common Stock (Proposal 3). |

13

#### TABLE OF CONTENTS

### Background
**On March 4, 2025, the Company consummated the Private Placement pursuant to the Purchase Agreement. The Purchase Agreement provided for the sale and issuance by the Company of an aggregate of 28,042,140 shares of the Company’s Common Stock, or, at the election of each Purchaser, Prefunded Warrants, with each share of Common Stock or Prefunded Warrant accompanied by (i) one Series A Warrants to purchase one Series A Warrant Share, and (ii) one Series B Warrants to purchase one Series B Warrant Share. The combined purchase price of $0.66 for each share of Common Stock, or $0.659 for each Prefunded Warrant in the Private Placement, together with one accompanying Series A Warrant and one accompanying Series B Warrant, represented the applicable “Minimum Price” in accordance with Listing Rule 5635(d) of Nasdaq.

The initial exercise price of each Series A Warrant is $1.32 per share of Common Stock. The Series A Warrants are exercisable only if the Warrant Stockholder Approval is obtained and expire five (5) years thereafter. The number of securities issuable under the Series A Warrant is subject to adjustment as described in more detail in the Series A Warrant. The Series A Warrant exercise price and the related number of shares of Common Stock issuable